Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells

Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells

Daratumumab is an anti-CD38 fully human IgG1 mAb approved for multiple myeloma treatment. One of the proposed mechanisms of action is the induction of antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells. NK cells acquire surface CD137 expression in the presence of solid-phase-attach...

Full description

Bibliographic Details
Main Authors: Maria C. Ochoa, Elisabeth Perez-Ruiz, Luna Minute, Carmen Oñate, Guiomar Perez, Inmaculada Rodriguez, Aintzane Zabaleta, Diego Alignani, Myriam Fernandez-Sendin, Ascension Lopez, Aura Muntasell, Miguel F. Sanmamed, Bruno Paiva, Miguel Lopez-Botet, Pedro Berraondo, Ignacio Melero
Format: Article
Language:English
Published: Taylor & Francis Group 2019-07-01
Series:OncoImmunology
Subjects:
nk cells
adcc
multiple myeloma
cd137
daratumumab
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1599636

Internet

http://dx.doi.org/10.1080/2162402X.2019.1599636

Similar Items